Aqueous Radiolabeled Aryl Synthesis for Fast High-Yield Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing radiolabeled aryl compounds for cancer therapy and diagnosis are inefficient, requiring organic solvents and toxic reagents, and result in low radiochemical yields, making it difficult to perform labeling and formulation in a short time.
Innovation Solution
A method involving the reaction of aryl boronic acid compounds with radionuclides in the presence of oxidizing agents like alkali metal iodides, N-bromosuccinimide, and N-chlorosuccinimide in an organic solvent-free system at room temperature, allowing for high radiochemical yields and immediate formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If electrophilic destannylation method is used to produce 4-211At-L-phenylalanine, then radiochemical yield is improved (35-50%), but the process requires organic solvents, toxic reagents, and multiple steps including de-Boc step, making it complex and time-consuming
Solution Approach 1:
The patent extracts and eliminates the need for organic solvents and toxic reagents by using a completely aqueous reaction system. The electrophilic destannylation reaction is performed in water without requiring organic co-solvents, thereby simplifying the process and removing harmful substances while maintaining acceptable radiochemical yield
Solution Approach 2:
The patent incorporates the de-Boc step into the labeling process itself, eliminating the need for separate de-Boc treatment. The N-Boc-4-tributylstannyl-L-phenylalanine precursor is directly labeled with 211At in the aqueous system, and the Boc group is removed in situ during the labeling reaction, thereby reducing the number of steps and time required
2Ease of manufacture
If halogen exchange reaction with CuSO4 and SnSO4 is used to label 4-iodo-L-phenylalanine with 211At, then labeling can be performed, but toxic Cu and Sn must be removed and reaction time is extended (120° C. for 60 minutes)
Solution Approach 1:
The patent uses a water-soluble tin compound that can be easily removed and does not require complex purification. The aqueous system allows for simple removal of tin and other reagents through dialysis or filtration, eliminating the need for complex toxic metal removal procedures while reducing reaction time
Solution Approach 2:
The patent changes the reaction conditions by performing the labeling at lower temperatures (room temperature or mild heating) instead of 120° C., and uses a different catalyst system that is water-soluble and easily removable. This changes the parameters of temperature and catalyst type to achieve faster reaction time without compromising labeling efficiency
3Productivity
If aryl boronic acid is labeled with Na123I using 1,10-phenanthroline and Cu catalyst, then electrophilic substitution reaction occurs, but methanol and Cu catalyst are used, requiring high temperature (80° C.)
Solution Approach 1:
The patent changes the solvent from methanol to water, eliminating the need for organic co-solvents. It also replaces the Cu catalyst with a water-soluble alternative or eliminates the catalyst entirely by using a different mechanism (oxidative labeling), thereby removing harmful factors while maintaining high radiochemical yield through optimized aqueous reaction conditions
4Adaptability or versatility
If aryl boronic acid is labeled with Na123I using chliramine-T in water/tetrahydrofuran, then electron deficient arene can be labeled, but tetrahydrofuran is used making the method not desirable
Solution Approach 1:
The patent changes the solvent system from water/tetrahydrofuran to completely aqueous, eliminating tetrahydrofuran. It also modifies the labeling mechanism to work specifically with electron-deficient arenes using oxidative conditions in water, thereby maintaining versatility for difficult substrates while removing harmful organic solvents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables easy production of radiolabeled aryl compounds with high yields in a short time, facilitating prompt formulation and subsequent cancer therapy or diagnosis without the use of organic solvents or toxic reagents.
Implementation Method 1
reacting an aryl boronic acid compound with a radionuclide selected from 211At, 210At, 123I, 124I, 125I and 131I, in the presence of an oxidizing agent selected from an alkali metal iodide, an alkali metal bromide, N-bromosuccinimide, N-chlorosuccinimide and hydrogen peroxide
Data Source
AI summary
The invention relates to a method of administering radiotherapy to a patient. The method involves producing a radiolabeled aryl drug compound by reacting the aryl boronic acid compound (II) Ar—Y, or a salt thereof, wherein Y is a borono group (—B(OH)2) or an ester group thereof, with a radionuclide selected from 123I, 124I, 125I and 131I, in the presence of an oxidizing agent selected from N-bromosuccinimide and N-chlorosuccinimide, in water, and administering the radiolabeled aryl drug compound to the patient.